| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Accurate HPV testing: a requirement for precision medicine for head and neck cancer
|
Seiwert, T.
|
|
|
24 |
11 |
p. 2711-2713
|
article
|
| 2 |
Advanced chondrosarcomas: role of chemotherapy and survival
|
Italiano, A.
|
|
|
24 |
11 |
p. 2916-2922
|
article
|
| 3 |
A meta-analysis on dose–response relationship between night shift work and the risk of breast cancer
|
Wang, F.
|
|
|
24 |
11 |
p. 2724-2732
|
article
|
| 4 |
A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study
|
DeCensi, A.
|
|
|
24 |
11 |
p. 2753-2760
|
article
|
| 5 |
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer
|
Ajani, J.A.
|
|
|
24 |
11 |
p. 2844-2849
|
article
|
| 6 |
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study † † Presented as oral presentation at ESMO 2012 in Vienna Austria.
|
Aerts, J.G.
|
|
|
24 |
11 |
p. 2860-2865
|
article
|
| 7 |
Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging
|
Darwiche, K.
|
|
|
24 |
11 |
p. 2866-2870
|
article
|
| 8 |
Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients
|
Flanagan, J.M.
|
|
|
24 |
11 |
p. 2813-2818
|
article
|
| 9 |
Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings
|
Abdel-Fatah, T.M.A.
|
|
|
24 |
11 |
p. 2801-2807
|
article
|
| 10 |
Cancer and the kidney: individualizing dosage according to renal function
|
Launay-Vacher, V.
|
|
|
24 |
11 |
p. 2713-2714
|
article
|
| 11 |
Central venous catheter care for the patients with cancer: ultrasound-guided insertion should be strongly recommended for internal jugular vein catheterization
|
Cavanna, L.
|
|
|
24 |
11 |
p. 2928-2929
|
article
|
| 12 |
Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial †
|
Jiang, Z.F.
|
|
|
24 |
11 |
p. 2766-2772
|
article
|
| 13 |
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology
|
Borbath, I.
|
|
|
24 |
11 |
p. 2824-2829
|
article
|
| 14 |
Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial
|
Falandry, C.
|
|
|
24 |
11 |
p. 2808-2813
|
article
|
| 15 |
Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states
|
Ades, F.
|
|
|
24 |
11 |
p. 2897-2902
|
article
|
| 16 |
Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose
|
Dooley, M.J.
|
|
|
24 |
11 |
p. 2746-2752
|
article
|
| 17 |
Editorial board
|
|
|
|
24 |
11 |
p. ii-iii
|
article
|
| 18 |
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
|
Maio, M.
|
|
|
24 |
11 |
p. 2911-2915
|
article
|
| 19 |
First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
|
Miles, D.W.
|
|
|
24 |
11 |
p. 2773-2780
|
article
|
| 20 |
GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study
|
Italiano, A.
|
|
|
24 |
11 |
p. 2922-2926
|
article
|
| 21 |
HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab
|
Zabaglo, L.
|
|
|
24 |
11 |
p. 2761-2766
|
article
|
| 22 |
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications
|
Montemurro, F.
|
|
|
24 |
11 |
p. 2715-2724
|
article
|
| 23 |
Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials
|
Rietbergen, M.M.
|
|
|
24 |
11 |
p. 2740-2745
|
article
|
| 24 |
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms †
|
Motzer, R.J.
|
|
|
24 |
11 |
p. 2927-2928
|
article
|
| 25 |
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial †
|
Denkert, C.
|
|
|
24 |
11 |
p. 2786-2793
|
article
|
| 26 |
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
|
Zinzani, P.L.
|
|
|
24 |
11 |
p. 2892-2897
|
article
|
| 27 |
Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy
|
Schweizer, M.T.
|
|
|
24 |
11 |
p. 2881-2886
|
article
|
| 28 |
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes †
|
Necchi, A.
|
|
|
24 |
11 |
p. 2887-2892
|
article
|
| 29 |
Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes
|
van der Heiden-van der Loo, M.
|
|
|
24 |
11 |
p. 2794-2801
|
article
|
| 30 |
Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer
|
Fagerholm, R.
|
|
|
24 |
11 |
p. 2780-2785
|
article
|
| 31 |
Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study †
|
Tyc-Szczepaniak, D.
|
|
|
24 |
11 |
p. 2829-2834
|
article
|
| 32 |
Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma
|
Hugen, N.
|
|
|
24 |
11 |
p. 2819-2824
|
article
|
| 33 |
Quality indicators in ovarian cancer surgery: Report from the French Society of Gynecologic Oncology (Société Française d'Oncologie Gynécologique, SFOG)
|
Querleu, D.
|
|
|
24 |
11 |
p. 2732-2739
|
article
|
| 34 |
Reduced risk of distant recurrence after adjuvant chemotherapy in patients with stage III colon cancer aged 75 years or older
|
van Erning, F.N.
|
|
|
24 |
11 |
p. 2839-2844
|
article
|
| 35 |
Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation
|
Suzuki, A.
|
|
|
24 |
11 |
p. 2854-2859
|
article
|
| 36 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis
|
Kim, H.S.
|
|
|
24 |
11 |
p. 2850-2854
|
article
|
| 37 |
Table of Contents
|
|
|
|
24 |
11 |
p. iv-vi
|
article
|
| 38 |
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
|
Ramalingam, S.
|
|
|
24 |
11 |
p. 2875-2880
|
article
|
| 39 |
Time to first cigarette and lung cancer risk in Japan
|
Ito, H.
|
|
|
24 |
11 |
p. 2870-2875
|
article
|
| 40 |
Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case–Control Consortium (PanC4)
|
Bosetti, C.
|
|
|
24 |
11 |
p. 2903-2910
|
article
|
| 41 |
Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial †
|
Deutsch, E.
|
|
|
24 |
11 |
p. 2834-2838
|
article
|
Journal description